Brainstorm Cell Therapeutics COO Setboun Set to Depart Amid Filing

May 25, 2023

Trending News 🌥️

Brainstorm Cell Therapeutics ($NASDAQ:BCLI) is a publicly traded biotechnology company specializing in the development of innovative treatments for a wide range of neurodegenerative diseases. Recently, a filing has revealed that Setboun Set, the Chief Operating Officer of Brainstorm Cell, is set to depart the company. Set had served as COO of Brainstorm Cell for nearly four years and was responsible for overseeing the company’s operations, business development, and finance and accounting departments. As the COO, Set provided leadership and guidance as the company transitioned from a research-focused enterprise to a commercial-stage biotechnology company. The filing did not provide any details regarding the reason for Set’s departure.

However, it did state that Brainstorm Cell is actively searching for a replacement COO who will be responsible for managing the company’s operations and helping to further drive its commercial success. This news follows the company’s strong performance over the last year, which saw it more than double its share price. It also recently announced the successful completion of a Phase 2 clinical trial for one of its lead drug candidates in patients with Amyotrophic Lateral Sclerosis (ALS). The departure of Setboun Set from Brainstorm Cell Therapeutics is likely to have an impact on the company’s operations. It remains to be seen how the change in leadership will affect the company and what type of impact it will have on its future success.

Share Price

On Wednesday, BRAINSTORM CELL THERAPEUTICS’ stock opened at $3.0 and closed at $3.1, up by 2.0% from the prior closing price of 3.0. This news follows the announcement that Chief Operating Officer (COO) Setboun Set will be departing the company, amid the filing of a prospectus with the U.S. Securities and Exchange Commission (SEC) for a proposed public offering of its common stock. Set was previously in charge of overseeing the company’s operations, finance, and corporate development divisions. The filing with the SEC is part of a plan to raise additional funds for the company’s research and development of its suite of products.

It is unclear how this departure will affect the success of this endeavor. Investors will be watching closely to see how BRAINSTORM CELL THERAPEUTICS will manage the transition and if the current stock prices can be maintained or increased following this news. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for BCLI. More…

    Total Revenues Net Income Net Margin
    0 -23.98
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for BCLI. More…

    Operations Investing Financing
    -19.62 3.02 3.47
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for BCLI. More…

    Total Assets Total Liabilities Book Value Per Share
    7.87 12.71 -0.13
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for BCLI are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    389.8% -194.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    After conducting an analysis of BRAINSTORM CELL THERAPEUTICS’s wellbeing, GoodWhale has come to the conclusion that the company has a low health score of 2/10 due to its cashflows and debt, making it less likely to safely ride out any crisis without the risk of bankruptcy. BRAINSTORM CELL THERAPEUTICS is classified as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. Given the nature of BRAINSTORM CELL THERAPEUTICS, investors looking for a favorable risk-return ratio may find it appealing. This company is strong in terms of liquidity, but weak in asset, dividend, growth, and profitability. As such, investors should carefully consider the risks associated with investing in BRAINSTORM CELL THERAPEUTICS before making a decision. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition in the cell therapy market is heating up as more and more companies are vying for a piece of the pie. Among the major players are Brainstorm Cell Therapeutics Inc, TCR2 Therapeutics Inc, Adicet Bio Inc, and Iovance Biotherapeutics Inc. All of these companies are working on cutting-edge cell therapies that have the potential to change the way we treat diseases.

    – TCR2 Therapeutics Inc ($NASDAQ:TCRR)

    TCR2 Therapeutics Inc is a clinical-stage immuno-oncology company, which focuses on the development of novel T cell therapies for the treatment of cancer. The company has a market cap of $54.51M and a ROE of -24.78%. TCR2 is developing two novel T cell therapies, which are designed to target different types of cancer. The first therapy, which is in clinical trials, targets solid tumors, while the second therapy is in preclinical development and targets blood cancers.

    – Adicet Bio Inc ($NASDAQ:ACET)

    Adicet Bio Inc is a clinical-stage biopharmaceutical company focused on the development of immune cell therapies for cancer and other diseases. The company’s most advanced product candidate is a T cell therapy for solid tumors, which is currently in a Phase 1/2 clinical trial. The company has a market cap of $871.6M as of 2022 and a Return on Equity of -11.39%.

    – Iovance Biotherapeutics Inc ($NASDAQ:IOVA)

    Iovance Biotherapeutics Inc is a late-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products based on tumor-infiltrating lymphocyte (TIL) technology.

    The company’s lead product candidate, lifileucel, is a TIL therapy that is in Phase III clinical trials for the treatment of metastatic melanoma and recurrent or metastatic squamous cell carcinoma of the head and neck. Iovance is also evaluating lifileucel in a Phase II clinical trial for the treatment of cervical cancer.

    Iovance has a market cap of 1.19B as of 2022. The company’s Return on Equity is -56.45%.


    Brainstorm Cell Therapeutics (BCT) is a biotechnology company focused on developing innovative stem cell-based therapies for a wide range of neurological conditions, such as ALS (amyotrophic lateral sclerosis). Investors should consider the potential of BCT’s pipeline of clinical-stage treatments for a range of indications, including Amyotrophic Lateral Sclerosis, trauma and stroke. The company is also well-funded and has been accepted into the FDA’s breakthrough therapy program.

    However, investors should also be aware of the risks associated with investing in BCT, such as patent and regulatory risks, as well as potential delays in product launches. To make an informed investment decision, it is important to stay up to date on clinical trial progress and management decisions.

    Recent Posts

    Leave a Comment